Gnubiotics Sciences Announces Funding From The Swiss Innovation Agency To Accelerate Development Of Glycopeptide Mediated Immunotherapies Against Solid Tumors
Gnubiotics Sciences Announces Funding From The Swiss Innovation Agency To Accelerate Development Of Glycopeptide Mediated Immunotherapies Against Solid Tumors
07/06/22, 8:00 AM
Location
Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides, today announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million (USD 1.4 million) will be supported by the grant from Innosuisse as well as contributions from Gnubiotics.